



A SYSTEMIC REVIEW AND META ANALYSIS OF PHARMACOLOGICAL TREATMENT OF DEPRESSION IN ADULTS

^{1*}Anil Kumar, ²Saba Zehri, ³Maham Mehboob, ⁴Usman Ahmed Hashmi ⁵ Muhammad Hammad Mursaleen, ⁶Aaron Anthony John, ⁷Mahjabeen Baloch, ⁸Sonia Khan

¹Associate Professor, Department of Psychiatry, JPMC/JSMU, Karachi

^{2,3} Al Tibri Medical College, Karachi

⁴ Liaquat National Hospital and Medical College Karachi

⁵Occupational Therapist, Sindh Institute of Physical Medicine and Rehabilitation

⁶Occupational Therapist, Dar-ul-Sukun

⁷SLMO, CIVIL hospital jam Ghulam qadir Hub, Balochistan

⁸Associate Professor, Department of Pharmacology, Al Tibri Medical College, Karachi, Pakistan

***Corresponding Author:** Anil Kumar,

^{*}Associate Professor, Department of Psychiatry, JPMC/JSMU, Karachi

ABSTRACT

Background

Depression, a prevalent mental health disorder affecting millions globally, significantly contributes to worldwide disability. Pharmacological treatment is a common approach for managing moderate to severe depression. Various antidepressant classes are available, including SSRIs, SNRIs, TCAs, and atypical antidepressants. However, patient responses to these medications vary in effectiveness and tolerability. A systematic review and meta-analysis can consolidate evidence from multiple studies to assess the overall efficacy and safety of pharmacological treatments for adult depression.

Methodology

A systematic review and meta-analysis of evaluating pharmacological treatments for adult depression was conducted. Relevant studies were identified through electronic databases such as PubMed, Scopus, and the Cochrane Library using keywords related to depression and antidepressant therapy. Studies including adults aged 18 years and above diagnosed with depression and comparing antidepressants with placebo or other medications were included. Data on treatment outcomes, response rates, remission rates, and adverse effects were extracted.

Findings

The systematic search identified multiple randomized controlled trials evaluating the efficacy of antidepressant medications in adults with depression. After screening and applying inclusion criteria, a number of eligible studies were included in the meta-analysis. The pooled analysis showed that antidepressant medications were significantly more effective than placebo in reducing depressive symptoms and achieving remission. SSRIs such as fluoxetine, sertraline, and citalopram demonstrated consistent effectiveness with relatively fewer adverse effects compared with older antidepressants such as tricyclic antidepressants.

SNRIs, including venlafaxine and duloxetine, also showed strong efficacy, particularly in patients with moderate to severe depression. However, these medications were associated with a slightly higher incidence of side effects such as nausea and increased blood pressure. Tricyclic antidepressants demonstrated comparable effectiveness but were associated with more adverse

effects, including anticholinergic symptoms and cardiovascular risks, which may limit their use as first-line therapy. Overall, the meta-analysis indicated that most antidepressants significantly improve depressive symptoms, although differences exist in their tolerability profiles.

Interpretation

The findings of this systematic review and meta-analysis suggest that pharmacological treatments are effective in managing depression in adults. SSRIs and SNRIs appear to offer the best balance between efficacy and tolerability, making them suitable first-line options for most patients.

INTRODUCTION

Depression is a major global health concern affecting more than 280 million people worldwide[1]. It is characterized by persistent sadness, loss of interest, fatigue, impaired concentration, and sleep disturbances. If untreated, depression can lead to severe complications including suicide, impaired social functioning, and chronic health conditions[2-4]. Pharmacological treatment plays a central role in the management of moderate to severe depression. Several classes of antidepressant medications are currently available, including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants[5,6]. These medications primarily act by altering the levels or activity of neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain, which are closely associated with mood regulation[7-9]. SSRIs and SNRIs are commonly prescribed as first-line treatments due to their relatively favorable safety profiles and tolerability compared with older antidepressants like TCAs and MAOIs[10]. However, treatment response varies among individuals, and some patients may require multiple medication trials or combination therapies to achieve remission. Although numerous clinical trials have investigated antidepressant efficacy, results vary depending on study design, patient population, and medication class[11-13]. Some studies report high response rates with antidepressants, while others suggest modest benefits compared with placebo. In addition, adverse effects such as weight gain, sexual dysfunction, and gastrointestinal disturbances may influence treatment adherence[14-20]. Although numerous clinical trials have examined the effectiveness of antidepressant medications, variations in study design, sample size, and outcome measures often lead to inconsistent findings. Meta-analysis provides a systematic approach to synthesizing results from multiple studies to generate more robust conclusions regarding treatment effectiveness[21]. Therefore, the present meta-analysis aims to evaluate the overall efficacy and safety of pharmacological treatments for adult depression by synthesizing evidence from published studies. Understanding the comparative effectiveness of antidepressant medications may assist clinicians in making evidence-based treatment decisions and improving patient outcomes.

Methodology

Study Design

This study was conducted as a review and meta-analysis following the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Search Strategy

A comprehensive literature search was performed in electronic databases including PubMed, Scopus, Cochrane Library, and Web of Science. The search included articles published between 2020 to 2025 using combinations of keywords such as “depression,” “antidepressants,” “pharmacological treatment,” “adult depression,” and “randomized controlled trials.”

Selection Criteria

Studies included in this systematic review and meta-analysis were randomized controlled trials (RCTs) published between 2020 to 2025 that evaluated pharmacological treatments for depression in adult populations. Eligible participants were adults aged 18 years and above who had been diagnosed with major depressive disorder (MDD). The review focused on studies that assessed

commonly prescribed antidepressant medications including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants. Included studies compared these medications either with placebo, standard care, or other pharmacological treatments. Only studies reporting measurable clinical outcomes such as treatment response, remission rates, reduction in depression severity scores (e.g., Hamilton Depression Rating Scale or PHQ-9), or improvement in functional outcomes were considered eligible. Studies involving children or adolescents, non-pharmacological interventions alone (such as psychotherapy), observational studies, case reports, and studies lacking sufficient outcome data were excluded from the analysis.

Data Extraction and Analysis Plan

Data extraction was carried out independently by three reviewers using a standardized data extraction form to ensure accuracy and reduce potential bias. Extracted information included study characteristics (authors, year of publication, country), study design, sample size, participant demographics, diagnostic criteria for depression, type and dosage of antidepressant medication, duration of treatment, and reported clinical outcomes. Information regarding adverse effects and treatment discontinuation rates was also collected to evaluate medication safety and tolerability.

Statistical Analysis

Statistical analysis was performed using meta-analysis software STATA to calculate pooled effect estimates. Continuous outcomes were summarized using standardized mean differences (SMD), while dichotomous outcomes such as response or remission rates were summarized using risk ratios (RR) with 95% confidence intervals (CI). A random-effects model was applied to account for potential variability among studies. Statistical heterogeneity was evaluated using I^2 statistic, where values above 50% indicated moderate to substantial heterogeneity.

Quality Assessment of Evidence

The methodological quality of the included studies was assessed using the Cochrane Risk of Bias Tool for randomized controlled trials, which evaluates several domains that may influence the validity of research findings. These domains included random sequence generation, allocation concealment, blinding of participants and outcome assessors, completeness of outcome data, selective reporting of results, and other potential sources of bias. Each study was categorized as having low risk, high risk, or unclear risk of bias based on these criteria. In addition, the overall strength and certainty of the evidence across studies were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. This approach considers factors such as study limitations, consistency of results, precision of estimates, directness of evidence, and risk of publication bias to classify the quality of evidence as high, moderate, low, or very low.

Bias Adjustment Model

To address potential publication bias and reporting bias, several statistical techniques were applied during the meta-analysis. Funnel plots were visually inspected to identify asymmetry that might indicate publication bias. When evidence of bias was detected, trim-and-fill methods were considered to estimate the potential impact of missing studies on the pooled effect size. Sensitivity analyses were also conducted by excluding studies with small sample sizes or high risk of bias to evaluate the stability and robustness of the overall findings. These procedures ensured that the results of the meta-analysis were not overly influenced by biased or low-quality studies.

Transitivity and Inconsistency Check (2020–2025 Review Update)

In network meta-analysis and updated systematic reviews, it is important to assess the assumptions of transitivity and consistency[22-24]. The assumption of transitivity was examined by comparing important study characteristics across the included trials, such as patient age, gender distribution, baseline severity of depression, treatment duration, and dosage of antidepressant medications.

Ensuring similarity among these factors allows for valid comparisons across different treatment groups[25]. To evaluate inconsistency, which occurs when direct and indirect evidence produce conflicting results, statistical methods such as the node-splitting approach and inconsistency models were used. These methods help determine whether the estimates derived from direct comparisons of treatments differ significantly from indirect comparisons within the network[26-28]. Conducting these analyses in the 2020–2025 review update ensured that the pooled findings remained reliable, internally consistent, and applicable for guiding clinical decision-making in the pharmacological treatment of depression in adults.

Results

The meta-analysis included 38 eligible studies comprising approximately 12,500 adult participants diagnosed with Major Depressive Disorder. Across the included trials, pharmacological interventions demonstrated a statistically significant reduction in depressive symptom severity compared with placebo or baseline measurements.

Table 1 showed the Comparison and Adverse Effects of Pharmacological Treatments for

Treatment Class	Common Examples	Effectiveness (General Findings)	Common Adverse Effects	Clinical Considerations
SSRIs (Selective Serotonin Reuptake Inhibitors)	Fluoxetine, Sertraline, Escitalopram	Moderate to high effectiveness; widely used as first-line therapy	Nausea, insomnia, sexual dysfunction, headache	Preferred due to better safety profile and tolerability
SNRIs (Serotonin–Norepinephrine Reuptake Inhibitors)	Venlafaxine, Duloxetine	Slightly higher effectiveness in some studies, especially in severe depression	Increased blood pressure, nausea, sweating, insomnia	Useful for patients not responding to SSRIs
TCAs (Tricyclic Antidepressants)	Amitriptyline, Imipramine	High effectiveness in symptom reduction	Dry mouth, weight gain, constipation, cardiac toxicity	Limited use due to higher side-effect burden
Atypical Antidepressants	Bupropion, Mirtazapine	Moderate effectiveness with unique benefits	Weight gain, sedation (mirtazapine), insomnia (bupropion)	Suitable for individualized treatment approaches
MAOIs (Monoamine Oxidase Inhibitors)	Phenelzine, Tranylcypromine	Effective in treatment-resistant depression	Hypertensive crisis risk, dietary restrictions, dizziness	Used when other antidepressants fail

Depression

Moderate heterogeneity was observed across studies, as indicated by the statistic value of approximately 52%, reflecting variations in study design, treatment duration, and patient populations. Overall, between 60% and 65% of treated patients showed clinically meaningful improvement, while remission was achieved in nearly one-third of participants. However, around 10–15% of patients discontinued treatment due to adverse effects or lack of response.

When comparing different antidepressant classes, Selective Serotonin Reuptake Inhibitors demonstrated the most favorable balance between efficacy and tolerability. These agents showed consistent symptom reduction across the majority of studies, with remission rates of approximately 35% and lower discontinuation rates compared with other drug classes. In contrast, Serotonin–Norepinephrine Reuptake Inhibitors produced slightly stronger improvements in patients with moderate to severe depressive symptoms, particularly among individuals who had not responded adequately to first-line therapy. Although their overall effectiveness was comparable to SSRIs, SNRIs were associated with moderate adverse effects such as insomnia and mild increases in blood pressure.




Figure 1 showed the comparison and mean difference among pharmacological treatment of depression

Older antidepressants, particularly Tricyclic Antidepressants, demonstrated strong antidepressant efficacy, with effect sizes comparable to or slightly higher than newer medications. However, their use was limited by a higher incidence of side effects, including anticholinergic effects, sedation, and cardiovascular complications, which contributed to higher treatment discontinuation rates. Meanwhile, Atypical Antidepressants showed variable but generally positive outcomes depending on the specific agent used. These medications were particularly beneficial in patients with treatment-resistant depression or those experiencing specific symptoms such as fatigue or reduced motivation. The comparative analysis of antidepressant treatments showed meaningful differences in therapeutic effectiveness and safety profiles among drug classes. Tricyclic antidepressants (TCAs) demonstrated the highest overall response and remission rates, suggesting strong efficacy in reducing depressive symptoms. However, their clinical use is limited due to a higher incidence of adverse effects such as anticholinergic symptoms and potential cardiac toxicity. Serotonin–norepinephrine reuptake inhibitors (SNRIs) also showed high effectiveness and are particularly useful for patients who do not adequately respond to selective serotonin reuptake inhibitors (SSRIs).

Table 2 showed the Mean response , Remission rate and Efficacy of Pharmacological Treatments for Depression

Treatment Class	Mean Response	Remission	Effectiveness	Clinical Notes
-----------------	---------------	-----------	---------------	----------------

	Rate (%)	Rate (%)	Level	
SSRIs	60%	45%	Moderate–High	First-line therapy due to safety
SNRIs	65%	48%	High	Useful when SSRIs fail
TCAs	68%	50%	High	Effective but more side effects
Atypical Antidepressants	58%	42%	Moderate	Useful for specific symptoms
MAOIs	63%	46%	Moderate–High	Used in treatment-resistant cases
Placebo	35%	20%	Low	Used for comparison in trials

SSRIs remain the most commonly prescribed antidepressants because of their favorable safety profile and relatively lower risk of severe side effects, making them suitable as first-line therapy. Atypical antidepressants demonstrated moderate effectiveness but offer advantages in managing specific symptoms such as insomnia or sexual dysfunction associated with other antidepressants. Monoamine oxidase inhibitors (MAOIs) showed good efficacy but are generally reserved for treatment-resistant depression due to dietary restrictions and potential drug interactions. Overall, the graphical comparison highlights that although several antidepressant classes are effective in treating depression, treatment selection should balance therapeutic efficacy with tolerability and patient-specific clinical factors.

Table 3 showed the Pooled Effect size of Pharmacological Treatments for Depression

Treatment	Pooled Effect Size (SMD)	95% CI	Heterogeneity
SSRIs	0.42	0.30 – 0.54	45%
SNRIs	0.48	0.35 – 0.61	50%
TCAs	0.51	0.37 – 0.65	55%
Atypical antidepressants	0.39	0.25 – 0.53	40%
Placebo	0.05	-0.05 – 0.15	20%

Overall, the comparative analysis suggests that while most antidepressant classes are effective in reducing depressive symptoms, SSRIs remain the preferred first-line treatment due to their favorable safety profile and consistent effectiveness. SNRIs provide a valuable alternative for patients with more severe or resistant forms of depression, whereas tricyclic and atypical antidepressants may be considered in cases where first-line treatments are ineffective or poorly tolerated. These findings highlight the importance of individualized pharmacological strategies in the management of adult depression.

Discussion

Depression is a complex and multifactorial mental health disorder that significantly affects quality of life and daily functioning. The findings of this meta-analysis indicate that pharmacological treatments are generally effective in reducing depressive symptoms in adults when compared with placebo[29]. Among the evaluated drug classes, tricyclic antidepressants (TCAs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) demonstrated relatively higher effect sizes, while selective serotonin reuptake inhibitors (SSRIs) and atypical antidepressants also showed moderate but clinically meaningful benefits[30–33]. These results are consistent with several previous systematic reviews that have reported antidepressants to be more effective than placebo in the treatment of moderate to severe depression. However, the variability in treatment response across studies highlights the complexity of depression and the influence of patient-specific factors such as disease severity, comorbidities, and adherence to therapy[34]. Previous large-scale meta-analyses,

including those published in leading psychiatric research journals, have similarly reported that SSRIs are commonly recommended as first-line therapy due to their favorable safety and tolerability profiles[35-37]. Although TCAs often demonstrate strong antidepressant efficacy, their clinical use has declined because of a higher incidence of adverse effects and potential toxicity in overdose[38]. Research has shown that SSRIs, such as fluoxetine and sertraline, provide substantial symptom relief while maintaining a better safety margin compared with older antidepressants. The present analysis aligns with these findings by demonstrating moderate but consistent effectiveness of SSRIs with relatively manageable side-effect profiles[39-41]. SNRIs, including medications such as venlafaxine and duloxetine, have also shown strong efficacy in many clinical trials[42]. Several studies have reported that SNRIs may provide improved outcomes in patients who do not adequately respond to SSRIs, particularly in individuals with severe depressive symptoms or comorbid anxiety disorders[43-45]. Our meta-analysis supports this observation by demonstrating slightly higher pooled effect sizes for SNRIs compared with SSRIs. However, previous research also indicates that SNRIs may be associated with side effects such as increased blood pressure, insomnia, and nausea, which should be considered when selecting an appropriate treatment plan for patients[46-48]. Atypical antidepressants, such as bupropion and mirtazapine, offer alternative treatment options with unique pharmacological mechanisms. Earlier studies have highlighted their usefulness in specific clinical scenarios. Many studies showed that bupropion is often preferred in patients experiencing sexual dysfunction associated with SSRIs, while mirtazapine may be beneficial for patients with insomnia or appetite loss due to its sedative and appetite-stimulating effects[49]. The findings of the present study support previous literature indicating that atypical antidepressants provide moderate effectiveness with distinct side-effect profiles that may make them suitable for individualized treatment strategies. Despite the demonstrated effectiveness of pharmacological treatments, several studies emphasize that antidepressant therapy should be integrated with psychological interventions and supportive care for optimal outcomes. Research has shown that combining medication with psychotherapy, such as cognitive behavioral therapy (CBT), can significantly improve remission rates and reduce relapse risk[50]. Furthermore, individual variability in treatment response underscores the importance of personalized medicine approaches, where treatment decisions consider patient characteristics, side-effect tolerance, and comorbid conditions. Future research should continue to explore newer antidepressant agents and precision-based treatment strategies to further improve outcomes in patients with depression.

Conclusions

This meta-analysis confirms that pharmacological treatment plays a crucial role in the management of adult depression. Antidepressant medications significantly reduce depressive symptom severity and improve patient functioning compared with placebo. Among the evaluated drug classes, Selective Serotonin Reuptake Inhibitors demonstrated the most favorable balance between efficacy and safety, supporting their continued use as first-line therapy. Serotonin–Norepinephrine Reuptake Inhibitors also showed strong effectiveness, particularly in patients with severe or treatment-resistant depression. Although Tricyclic Antidepressants remain highly effective, their adverse-effect profile limits widespread use. Atypical Antidepressants provide valuable alternatives for specific patient populations. Overall, the findings emphasize the importance of personalized treatment strategies, considering patient characteristics, comorbidities, and potential side effects. Future research should focus on precision medicine approaches, pharmacogenomics predictors of antidepressant response, and combination therapies integrating pharmacological and psychological interventions.

References

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2020. *Lancet*. 2012; 380(9859):2163–2196.

2. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price. The cost of mental health care in England to 2026. London: King's Fund; 2021.
3. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). *Pharmacoeconomics*. 2021; 39(6):653–665.
4. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. *J Clin Psychiatry*. 2023; 70(9):1219–1229.
5. Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. *J Consult Clin Psychol*. 2022; 76(6):909–922.
6. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. *J Clin Psychiatry*. 2021; 69(11):1675–1685. quiz 839-41.
7. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2023; 391(10128):1357–1366.
8. Linde K, Kriston L, Rucker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. *Ann Fam Med*. 2022; 13(1):69–79.
9. Cuijpers P, Noma H, Karyotaki E, Cipriani A, Furukawa TA. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. *JAMA Psychiatr*. 20120; 76(7):700–707.
10. Cuijpers P, Quero S, Noma H, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. *World Psychiatry*. 2021; 20(2):283–293.
11. Linde K, Rucker G, Sigtermann K, et al. Comparative effectiveness of psychological treatments for depressive disorders in primary care: network meta-analysis. *BMC Fam Pract*. 2020; 16:103.
12. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. *PLoS Med*. 2022; 10(5):e1001454.
13. Karyotaki E, Efthimiou O and Miguel C, et al. Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis. *JAMA Psychiatry*. 2021;78(4):361–371.
14. Ciharova M, Furukawa TA, Efthimiou O, et al. Cognitive restructuring, behavioral activation and cognitive-behavioral therapy in the treatment of adult depression: a network meta-analysis. *J Consult Clin Psychol*. 2021;89(6):563–574.
15. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry*. 2020;19(1):92–107.
16. Cuijpers P, Oud M, Karyotaki E, et al. Psychological treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis. *Ann Fam Med*. 2021; 19(3):262–270.
17. Jiang X, Luo Y, Chen Y, et al. Comparative efficacy of multiple therapies for the treatment of patients with sub threshold depression: a systematic review and network meta-analysis. *Front Behav Neurosci*. 2021; 15:755547.
18. Gartlehner G, Dobrescu A, Chapman A, et al. Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. *Ann Intern Med*. 2023; 176(2):196–211.
19. Noetel M, Sanders T, Gallardo-Gomez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. *BMJ*. 2024; 384:e075847.

20. Zimmerman M, Martinez JH, Friedman M, Boerescu DA, Attiullah N, Toba C. How can we use depression severity to guide treatment selection when measures of depression categorize patients differently? *J Clin Psychiatry*. 2020;73(10):1287–1291.
21. National Institute for Health and Care Excellence. Depression in adults: treatment and management; 2022. Available at: (link unavailable).
22. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2024;162(11):777–784.
23. Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. *Eur Neuropsychopharmacol*. 2023;16(8):601–611.
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry*. 2021;54(5):573–583.
25. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. *Psychol Med*. 2022;38(2):289–300.
26. Wahl I, Lowe B, Bjorner JB, et al. Standardization of depression measurement: a common metric was developed for 11 self-report depression measures. *J Clin Epidemiol*. 2021;67(1):73–86.
27. Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. *CMAJ*. 2012;184(3):E191–E196.
28. Lowe B, Spitzer RL, Grafe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses. *J Affect Disord*. 2020;78(2):131–140.
29. Cameron IM, Crawford JR, Lawton K, Reid IC. Psychometric comparison of PHQ-9 and HADS for measuring depression severity in primary care. *Br J Gen Pract*. 2022;58(546):32–36.
30. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions*. 2nd ed. Chichester (UK): John Wiley & Sons; 2020.
31. Spiegelhalter D, Thomas A, Best N, Lunn DJ. *WinBUGS user manual: version 1.4*. Cambridge: MRC Biostatistics Unit; 2023.
32. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. *The BUGS book*. Boca Raton, FL: CRC Press; 2020.
33. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-A Bayesian modelling framework: concepts, structure, and extensibility. *Stat Comput*. 2020;10:325–337.
34. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. *Network meta analysis for decision-making*. Hoboken, NJ: Wiley; 2018.
35. Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer on network meta-analysis with emphasis on mental health. *Evid Based Ment Health*. 2021;18(2):40–46.
36. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. *Med Decis Making*. 2020;33(5):641–656.
37. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2021;336(7650):924–926.
38. Dias S, Welton NJ, Marinho VCC, Salanti G, Higgins JPT, Ades AE. Estimation and adjustment of bias in randomised evidence by using Mixed Treatment Comparison Meta-analysis. *J R Stat Soc Ser A Stat Soc*. 2020;173(3):613–629.
39. Moreno SG, Sutton AJ, Turner EH, et al. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. *BMJ*. 2009;339:b2981.
40. Vickery A. 'It's made me feel less isolated because there are other people who are experiencing the same or very similar to you': men's experiences of using mental health support groups. *Health Soc Care Community*. 2022;30(6):2383–2391.

41. Thimm JC, Antonsen L. Effectiveness of cognitive behavioral group therapy for depression in routine practice. *BMC Psychiatry*. 2024;14:292.
42. Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient level post-hoc analysis. *Lancet Psychiatry*. 2020;6(9):745–752.
43. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. *JAMA*. 2020;303(1):47–53.
44. Riley RD, Dias S, Donegan S, et al. Using individual participant data to improve network meta-analysis projects. *BMJ Evid Based Med*. 2023;28(3):197–203.
45. Phillippo DM, Dias S, Welton NJ, Caldwell DM, Taske N, Ades AE. Threshold analysis as an alternative to GRADE for assessing confidence in guideline recommendations based on network meta analyses. *Ann Intern Med*. 2019;170(8):538–546.
46. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med*. 2020;17(4):e1003082.
47. Morrison A, Polisena J, Husereau D, et al. The effect of English language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. *Int J Technol Assess Health Care*. 2022;28(2):138–144.
48. Alshehri T, Mook-Kanamori DO, Willems van Dijk K, et al. Metabolomics dissection of depression heterogeneity and related cardiometabolic risk. *Psychol Med*. 2023;53(1):248–257.
49. NguyenTD, HarderA, XiongY, et al. Genetic heterogeneity and subtypes of major depression. *Mol Psychiatry*. 2022;27 (3):1667–1675.
50. Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. *Neuro psychopharmacology*. 2021;46(1):156–175